# Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT04809766** · PHASE1 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Autologous Mesothelin-specific TCR-T Cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04809766
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-14
- **Primary completion:** 2024-10-24
- **Final completion:** 2025-01-15
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study terminated due to end of funding.
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04809766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04809766, "Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04809766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*